共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease显示文摘The prevalence of obesity and related conditions like non-alcoholic fatty liver disease(NAFLD) is increasing worldwide and therapeutic options are limited.Alternative treatment options are therefore intensively sought after.An interesting candidate is the natural polyphenol resveratrol(RSV) that activates adenosinmonophosphate-activated protein kinase(AMPK) and silent information regulation-2 homolog 1(SIRT1).In addition,RSV has known anti-oxidant and anti-inflammatory effects.Here,we review the current evidence for RSVmediated effects on NAFLD and address the different aspects of NAFLD and non-alcoholic steatohepatitis(NASH) pathogenesis with respect to free fatty acid(FFA) flux from adipose tissue,hepatic de novo lipogenesis,inadequate FFA β-oxidation and additional intra- and extrahepatic inflammatory and oxidant hits.We review the in vivo evidence from animal studies and clinical trials.The abundance of animal studies reports a decrease in hepatic triglyceride accumulation,liver weight and a general improvement in histological fatty liver changes,along with a reduction in circulating insulin,glucose and lipid levels.Some studies document AMPK or SIRT1 activation,and modulation of relevant markers of hepatic lipogenesis,inflammation and oxidation status.However,AMPK/SIRT1-independent actions are also likely.Clinical trials are scarce and have primarily been performed with a focus on overweight/obese participants without a focus on NAFLD/NASH and histological liver changes.Future clinical studies with appropriate design are needed to clarify the true impact of RSV treatment in NAFLD/NASH patients. | Sara Heebll Karen Louise Thomsen Steen B Pedersen Hendrik Vilstrup Jacob George Henning Grnbk | 2014 | World Journal of Hepatology2014，6，4： | 11 |
| 2 | 疏肝健脾方药对LXRα/FAS信号通路介导非酒精性脂肪性肝病大鼠肝细胞脂肪沉积的影响显示文摘目的探讨疏肝健脾方药对LXRα/FAS信号通路介导非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)大鼠肝细胞脂肪沉积的影响。方法选用SPF级雄性SD大鼠75只,共分5组,每组15只,分别为:正常组,模型组,疏肝组,健脾组及合方组;除正常组,其余均各组采用高脂饮食复制NAFLD大鼠模型,给药各组分别给予疏肝方(柴胡疏肝散)、健脾方(参苓白术散)、合方(柴胡疏肝散和参苓白术散合方)进行干预,采用全自动生化分析肝脂改变,分离出肝细胞,Typan blue染色和流式细胞术(FCM)对肝细胞的活性及纯度进行鉴定。采用实时定量PCR法检测肝细胞LXRαmRNA、FAS mRNA的表达,采用Western blot法检测LXRα、FAS蛋白在肝细胞中的表达。结果 (1)油红O染色后模型组的NAFLD大鼠病理结构显示肝细胞肿胀,细胞核位于细胞边缘,细胞浆内可见大小不等的小空泡,部分肝细胞小空泡融合成大泡等特征性改变,提示成功建立高脂饮食诱导NAFLD大鼠实验动物模型。各组中药对NAFLD病理结构改变均有不同程度的修复作用,尤以疏肝组明显。(2)与正常组比较,模型组肝细胞LXRα、FAS基因及蛋白的表达水平均明显升高(P<0.01);与模型组比较,健脾方和疏肝方组的表达水平下调明显(P<0.01,P<0.05)。结论 LXRα/FAS通路是介导NAFLD脂质平衡代谢紊乱重要的信号通路,疏肝健脾方药能够调控肝细胞LXRα/FAS通路使NAFLD大鼠肝细胞脂肪沉积趋于恢复,这可能是疏肝健脾方药抗实验性大鼠脂肪肝的作用机制之一。 | 龚享文 杨钦河 闫海震 张玉佩 黄进 徐拥建 张金文 林春梅 | 2014 | 中国中西医结合杂志2014，34，12： | 8 |
您所在的机构暂未开通此部分的功能，请联系管理员